Natera stung for $57m in prenatal screening clash

Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera

25 January 2024 Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.

Americas

Natera files patent lawsuit over DNA technology

1 August 2023 The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.

Medtech

Delaware jury awards $96.3m damages to Natera over kidney transplant tests

30 January 2024 Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.

More on this story

Americas

Natera files patent lawsuit over DNA technology

1 August 2023 The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.

Big Pharma

Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera

25 January 2024 Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.

Medtech

Delaware jury awards $96.3m damages to Natera over kidney transplant tests

30 January 2024 Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.

More on this story

Americas

Natera files patent lawsuit over DNA technology

1 August 2023 The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.

Big Pharma

Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera

25 January 2024 Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.

Medtech

Delaware jury awards $96.3m damages to Natera over kidney transplant tests

30 January 2024 Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Natera stung for $57m in prenatal screening clash

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features